GlassScriptPhysician profile
Claudia Perez
NPI 1821616467
$400.20
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $68.42 | 2021 | |
| Astellas Pharma US INC | $67.72 | 2021 | |
| Mylan Specialty L.P. | $53.76 | 2021 | |
| Merck Sharp & Dohme LLC | $50.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.96 | 2021 | |
| Amgen INC. | $25.67 | 2021 | |
| Glaxosmithkline, LLC. | $17.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.68 | 2021 | |
| Dexcom, INC. | $14.09 | 2021 | |
| Pfizer INC. | $13.18 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.05 | 2021 | |
| Si-Bone, INC. | $11.57 | 2021 | |
| Insulet Corporation | $11.43 | 2021 | |
| Genentech USA, INC. | $3.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.